Chiltern establishes new office in Netherlands
Chiltern is a clinical contract research organization (CRO) with experience in the management of Phase I-IV clinical trials across a range of therapeutic areas, functional service provision and
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.